Pedro Clavero

Pedro Clavero

Auto-generated profile, based on publicly available information

Pedro Clavero

Servicio de Neurología, Complejo Hospitalario de Navarra, Pamplona, Spain

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2013 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
EMElena H Martínez-Lapiscina
Elena H Martínez-Lapiscina
PCPedro Clavero
Pedro Clavero
ETEstefania Toledo
Estefania Toledo
RERamon Estruch
Ramon Estruch
Jordi Salas-SalvadóJordi Salas-Salvadó
Jordi Salas-Salvadó
MMMiguel A. Martinez-Gonzalez
Miguel A. Martinez-Gonzalez
Previous observational studies reported beneficial effects of the Mediterranean diet (MedDiet) on cognitive function, but results were inconsistent. We assessed the effect on cognition of a nutritional intervention using MedDiets in comparison with a low-fat control diet. We assessed 522 participants at high vascular risk (44.6% men, age 74.6 ± 5.7 years at cognitive evaluation) enrolled in a multicentre, randomised, primary prevention trial (PREDIMED), after a nutritional intervention comparing two MedDiets (supplemented with either extra-virgin olive oil (EVOO) or mixed nuts) versus a low-fat control diet. Global cognitive performance was examined by Mini-Mental State Examination (MMSE) and Clock Drawing Test (CDT) after 6.5 years of nutritional intervention. Researchers who assessed the outcome were blinded to group assignment. We used general linear models to control for potential confounding. After adjustment for sex, age, education, Apolipoprotein E genotype, family history of cognitive impairment/dementia, smoking, physical activity, body mass index, hypertension, dyslipidaemia, diabetes, alcohol and total energy intake, participants allocated to the MedDiet+EVOO showed higher mean MMSE and CDT scores with significant differences versus control (adjusted differences: +0.62 95% CI +0.18 to +1.05, p=0.005 for MMSE, and +0.51 95% CI +0.20 to +0.82, p=0.001 for CDT). The adjusted means of MMSE and CDT scores were also higher for participants allocated to the MedDiet+Nuts versus control (adjusted differences: +0.57 (95% CI +0.11 to +1.03), p=0.015 for MMSE and +0.33 (95% CI +0.003 to +0.67), p=0.048 for CDT). These results did not differ after controlling for incident depression. An intervention with MedDiets enhanced with either EVOO or nuts appears to improve cognition compared with a low-fat diet. ISRCTN:35739639.

18 March 2013 in The Journal of nutrition, health and aging
Verified
Journal Article
Open access
PDF file
EMElena H. Martinez-Lapiscina
Elena H. Martinez-Lapiscina
PCP. Clavero
P. Clavero
ETEstefania Toledo
Estefania Toledo
BJB. San Julian
B. San Julian
ASA. Sanchez-Tainta
A. Sanchez-Tainta
MMMiguel A. Martinez-Gonzalez
Miguel A. Martinez-Gonzalez
XXXto assess the effect on cognition of a controlled intervention testing Mediterranean diets (MedDiet).

20 June 2014 in Brain
Verified
Journal Article
Open access
PDF file
RGRafael González-Redondo
Rafael González-Redondo
DGDavid García-García
David García-García
PCPedro Clavero
Pedro Clavero
Carmen Gasca-SalasCarmen Gasca-Salas
Carmen Gasca-Salas
DGDr. Garcia-Eulate
Dr. Garcia-Eulate
MRMaría Cruz Rodríguez-Oroz
María Cruz Rodríguez-Oroz
The pathophysiological process underlying cognitive decline in Parkinson’s disease is not well understood. Cerebral atrophy and hypometabolism have been described in patients with Parkinson’s disease and dementia or mild cognitive impairment with respect to control subjects. However, the exact relationships between atrophy and hypometabolism are still unclear. To determine the extension and topographical distribution of hypometabolism and atrophy in the different cognitive states of Parkinson’s disease, we examined 46 patients with Parkinson’s disease (19 female, 27 male; 71.7 ± 5.9 years old; 14.6 ± 4.2 years of disease evolution; modified Hoehn and Yahr mean stage 3.1 ± 0.7). Cognitive status was diagnosed as normal in 14 patients, as mild cognitive impairment in 17 and as dementia in 15 patients. Nineteen normal subjects (eight female, 11 male; 68.1 ± 3.2 years old) were included as controls. 18F-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging scans were obtained, co-registered, corrected for partial volume effect and spatially normalized to the Montreal Neurological Institute space in each subject. Smoothing was applied to the positron emission tomography and magnetic resonance imaging scans to equalize their effective smoothness and resolution (10 mm and 12 mm full-width at half-maximum and Gaussian kernel, respectively). Z-score maps for atrophy and for hypometabolism were obtained by comparing individual images to the data set of control subjects. For each group of patients, a paired Student’s t-test was performed to statistically compare the two Z-map modalities (P < 0.05 false discovery rate corrected) using the direct voxel-based comparison technique. In patients with mild cognitive impairment, hypometabolism exceeded atrophy in the angular gyrus, occipital, orbital and anterior frontal lobes. In patients with dementia, the hypometabolic areas observed in the group with mild cognitive impairment were replaced by areas of atrophy, which were surrounded by extensive zones of hypometabolism. Areas where atrophy was more extended than hypometabolism were found in the precentral and supplementary motor areas in both patients with mild cognitive impairment and with dementia, and in the hippocampus and temporal lobe in patients with dementia. These findings suggest that there is a gradient of severity in cortical changes associated with the development of cognitive impairment in Parkinson’s disease in which hypometabolism and atrophy represent consecutive stages of the same process in most of the cortical regions affected.

1 September 2019 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
DGDiego Santos García
Diego Santos García
TFT. de Deus Fonticoba
T. de Deus Fonticoba
ECE. Suárez Castro
E. Suárez Castro
CBC. Borrué
C. Borrué
MMM. Mata
M. Mata
VIVillar
Villar

8 August 2012 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
DGDavid Garcia-Garcia
David Garcia-Garcia
PCPedro Clavero
Pedro Clavero
Carmen Gasca-SalasCarmen Gasca-Salas
Carmen Gasca-Salas
ILIsabel Lamet
Isabel Lamet
Javier ArbizuJavier Arbizu
Javier Arbizu
MRMaría Cruz Rodríguez-Oroz
María Cruz Rodríguez-Oroz

18 May 2009 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
MRMaría Cruz Rodríguez-Oroz
María Cruz Rodríguez-Oroz
PLPablo Martínez Lage
Pablo Martínez Lage
JSJose V. Sanchez-Mut
Jose V. Sanchez-Mut
ILIsabel Lamet
Isabel Lamet
JPJavier Pagonabarraga
Javier Pagonabarraga
JOJose A. Obeso
Jose A. Obeso